Brief: Rigel Pharmaceuticals Q1 EPS USD -0.05 Vs. IBES Estimate USD -0.03
07/05/2024 21:01
May 07 (Reuters) - Rigel Pharmaceuticals Q1 net income USD -8.2 million vs. IBES estimate USD -5.36 million. * Q1 revenue USD 29.5 million vs. IBES estimate USD 31.3 million
Recent news on Rigel Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)